Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Hopstem Biotechnology Inc.
Hopstem Announces the first Closing of Series C Financing to Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy
August 10, 2026
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
July 29, 2026
Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy
June 3, 2026
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026